2. Academic Validation
  3. First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo

First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo

  • J Med Chem. 2024 Feb 22;67(4):2963-2985. doi: 10.1021/acs.jmedchem.3c02053.
Sachin Sharma 1,  Shao-An Wang 2,  Wen-Bin Yang 3,  Hong-Yi Lin 4,  Mei-Jung Lai 5,  Hsien-Chung Chen 3 6 7,  Tzu-Yuan Kao 1 7,  Feng-Lin Hsu 2,  Kunal Nepali 1 5 8,  Tsung-I Hsu 3 5 7 9 10,  Jing-Ping Liou 1 5 10 8
Affiliations

Affiliations

  • 1 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan.
  • 2 School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
  • 3 TMU Research Center of Neuroscience, Taipei Medical University, Taipei 110, Taiwan.
  • 4 Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
  • 5 TMU Research Center for Drug Discovery, Taipei Medical University, Taipei 110, Taiwan.
  • 6 Department of Neurosurgery, Shuang Ho Hospital, Taipei Medical University, Taipei 110, Taiwan.
  • 7 Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei 110, Taiwan.
  • 8 Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan.
  • 9 International Master Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
  • 10 TMU Research Center of Cancer Translational Medicine, Taipei 110 Taiwan.
PMID: 38285511 DOI: 10.1021/acs.jmedchem.3c02053
Abstract

Structural analysis of tazemetostat, an FDA-approved EZH2 Inhibitor, led us to pinpoint a suitable site for appendage with a pharmacophoric fragment of second-generation HSP90 inhibitors. Resultantly, a magnificent dual EZH2/HSP90 Inhibitor was pinpointed that exerted striking cell growth inhibitory efficacy against TMZ-resistant Glioblastoma (GBM) cell lines. Exhaustive explorations of chemical probe 7 led to several revelations such as (i) compound 7 increased Apoptosis/necrosis-related gene expression, whereas decreased M phase/kinetochore/spindle-related gene expression as well as CENPs protein expression in Pt3R cells; (ii) dual inhibitor 7 induced cell cycle arrest at the M phase; (iii) compound 7 suppressed Reactive Oxygen Species (ROS) catabolism pathway, causing the death of TMZ-resistant GBM cells; and (iv) compound 7 elicited substantial in vivo anti-GBM efficacy in experimental mice xenografted with TMZ-resistant Pt3R cells. Collectively, the study results confirm the potential of dual EZH2-HSP90 inhibitor 7 as a tractable anti-GBM agent.

Figures
Products